CA2685636C - Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine - Google Patents

Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine Download PDF

Info

Publication number
CA2685636C
CA2685636C CA2685636A CA2685636A CA2685636C CA 2685636 C CA2685636 C CA 2685636C CA 2685636 A CA2685636 A CA 2685636A CA 2685636 A CA2685636 A CA 2685636A CA 2685636 C CA2685636 C CA 2685636C
Authority
CA
Canada
Prior art keywords
metformin
pharmaceutically acceptable
acceptable salt
combination
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2685636A
Other languages
English (en)
Other versions
CA2685636A1 (fr
Inventor
Louise Silvestre
Caroline Sert-Langeron
Tianyue Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to CA2685636A priority Critical patent/CA2685636C/fr
Publication of CA2685636A1 publication Critical patent/CA2685636A1/fr
Application granted granted Critical
Publication of CA2685636C publication Critical patent/CA2685636C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Une méthode de traitement du diabète sucré de type 2 comprend ladministration de (c) desPro36Exendin-4(1-39)-Lys6-NH2 ou/et un sel pharmaceutiquement acceptable de celui-ci et (d) de la metformine ou/et un sel pharmaceutiquement acceptable de celle-ci, à un sujet en ayant besoin.
CA2685636A 2009-11-13 2009-11-13 Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine Active CA2685636C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2685636A CA2685636C (fr) 2009-11-13 2009-11-13 Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2685636A CA2685636C (fr) 2009-11-13 2009-11-13 Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine

Publications (2)

Publication Number Publication Date
CA2685636A1 CA2685636A1 (fr) 2011-05-13
CA2685636C true CA2685636C (fr) 2017-02-21

Family

ID=43989538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2685636A Active CA2685636C (fr) 2009-11-13 2009-11-13 Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine

Country Status (1)

Country Link
CA (1) CA2685636C (fr)

Also Published As

Publication number Publication date
CA2685636A1 (fr) 2011-05-13

Similar Documents

Publication Publication Date Title
US20110118180A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
EP2324853B1 (fr) Lixisenatide en tant que traitement d'appoint à la metformine dans le diabète de type 2
JP6676108B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
US11026999B2 (en) Insulin glargine/lixisenatide fixed ratio formulation
EP2329848B1 (fr) Lixisénatide en tant que traitement d'appoint à l'insuline glargine et à la metformine dans le diabète de type 2
US20110118178A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
KR20140041409A (ko) ２형 진성 당뇨병 환자에서 저혈당증의 예방
JP6857129B2 (ja) ２型糖尿病患者処置
CA2685638C (fr) Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine
JP5980466B2 (ja) インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法
CA2685636C (fr) Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine
KR20110052990A (ko) 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
US20210093698A1 (en) Treatment of type 2 diabetes mellitus
AU2009238272A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
JP2011105609A (ja) メトホルミンへの付加療法を含む２型糖尿病の治療方法
MX2009012310A (es) Metodo de tratamiento de diabetes tipo 2 que comprende terapia de adicion a metformina.
KR20110052987A (ko) 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
AU2009238271B2 (en) Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
MX2009012308A (es) Metodo de tratamiento de diabetes tipo 2 que comprende terapia de adicion a insulina glargina y metformina.
BRPI0904430A2 (pt) método de tratamento de diabetes do tipo 2 compreendendo terapia adjuvante à metformina

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141029